Influenza, Human
Conditions
Keywords
Influenza, Safety, Reactogenicity, Immunogenicity, mRNA vaccine, Healthy younger adults, Healthy older adults
Brief summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Interventions
BIOLOGICALF2G22B/DL001Z
Study intervention was administered intramuscularly at Day 1.
BIOLOGICALF2H23D/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
BIOLOGICALF2H23B/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
BIOLOGICALF2H23H/DL001Z
Study intervention was administered intramuscularly at Day 1.
COMBINATION_PRODUCTFDQ23A-NH (Flu D-QIV)
Control Vaccine was administered intramuscularly at Day 1.
BIOLOGICALGSK5800544A
Study intervention was administered intramuscularly at Day 1.
COMBINATION_PRODUCTFlu D-TIV
Control Vaccine was administered intramuscularly at Day 1.
BIOLOGICALF2H23A/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
BIOLOGICALF2H23G/DL001Z
Study intervention was administered intramuscularly at Day 1.
COMBINATION_PRODUCTFluzone HD Quadrivalent
Control vaccine was administered intramuscularly at Day 1.
COMBINATION_PRODUCTFluzone HD
Control vaccine was administered intramuscularly at Day 1.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This is an observer blind study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. A male or female between and including 18 and 85 years of age (YAs: 18-64; OAs: 65-85) at the time of the study intervention administration. 2. Healthy participants or medically stable patients as established by medical history and clinical examination. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, hepatic, neurologic, and hematologic diseases) are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment. 3. Body mass index (BMI) \>=18 Kilograms per meter square (kg/m²) and less than or equal to (\<=) 35kg/m2. 4. Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits), independently or with the assistance of a caregiver. 5. Written informed consent obtained from the participant prior to performance of any study-specific procedure. 6. Female participants of non-childbearing potential may be enrolled in the clinical study. 7. Female participants of childbearing potential may be enrolled in the clinical study, if the participant: * Has practiced adequate contraception for 1 month prior to the study intervention administration, and * Has a negative pregnancy test within 24 hours prior to the study intervention administration, and * Has agreed to continue adequate contraception for at least 1 month after study intervention administration.
Exclusion criteria
1. Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1. 2. Current or past malignancy, unless completely resolved without sequelae for greater than (\>) 5 years before the study intervention administration (excluding effectively treated basal cell skin cancer). 3. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required). HIV-infected individuals may be enrolled if they have been stable on antiretroviral therapy for the past 6 consecutive months, i.e., their treatment has not been modified, their cluster of differentiation 4 (CD4) cell count is \>= 200/ cubic millimeter (mm³) and their viral load has been undetectable (i.e., HIV-RNA lesser than (\<) 50 copies/milliliter \[mL\]) (based on medical records, no laboratory testing required). 4. Participants with a history of, or current suspicion of myocarditis, pericarditis, or idiopathic cardiomyopathy (including a history of myocarditis or pericarditis following vaccination with an mRNA COVID-19 vaccine), or presence of any medical condition that increases risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection will be excluded from the study. 5. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention (including polyethylene glycol, egg proteins and aminoglycoside antibiotics). 6. Hypersensitivity to latex. 7. Recurrent history or uncontrolled neurological disorders or seizures, including Guillain-Barré syndrome and Bell's palsy, with the exception of febrile seizures during childhood. 8. Any history of dementia or any medical condition that moderately or severely impairs cognition. 9. Any condition that in the judgment of the investigator would make intramuscular injection unsafe. 10. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study. 11. Administration of an influenza vaccine within 180 days before enrollment or planned administration prior to Visit 2 (Day 29) after the study intervention administration. 12. Previous vaccination with a mRNA influenza vaccine. 13. Administration of a vaccine not foreseen by the study protocol in the period starting 30 days (Day -30) before the study intervention administration, or planned administration within 28 days (Visit 2 \[Day 29\]) after the study intervention administration\*. * If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and sponsor is notified. 14. Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period. 15. Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration or planned administration during the study period. 16. Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study. * Up to 3 months prior to the study intervention administration: For corticosteroids, this will mean prednisone equivalent \>=20 mg/day. Inhaled, intraarticular and topical steroids are allowed. * Up to 3 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication. 17. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). 18. Pregnant or lactating female participant. 19. Bedridden participants. 20. Female participant planning to become pregnant or planning to discontinue contraceptive precautions within the 1-month post-dosing period. 21. History of chronic alcohol consumption and/or drug abuse in the past 5 years as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures. 22. Any study personnel or their immediate dependents, family, or household members. 23. Participants with extensive tattoos covering deltoid region on both arms that would preclude the assessment of local reactogenicity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1 YA: Geometric Mean Titer (GMT) of Antigen 1 Antibody Titer | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 YA: GMT of Antigen 1 Antibody Titer | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 OA: GMT of Antigen 1 Antibody Titer | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 OA: GMT of Antigen 1 Antibody Titer | At Day 29 | Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 YA: Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers | From Day 1 (baseline) to Day 29 | GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 YA: GMI of Antigen 1 Antibody Titers | From Day 1 (baseline) to Day 29 | GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 OA: GMI of Antigen 1 Antibody Titers | From Day 1 (baseline) to Day 29 | GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 OA: GMI of Antigen 1 Antibody Titers | From Day 1 (baseline) to Day 29 | GMI is defined as the geometric mean of the ratios of the post dosing titer over the Day 1 titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR) | From Day 1 (baseline) to Day 29 | SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 YA: Percentage of Participants With Antigen 1 Antibody SCR | From Day 1 (baseline) to Day 29 | SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 OA: Percentage of Participants With Antigen 1 Antibody SCR | From Day 1 (baseline) to Day 29 | SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 OA: Percentage of Participants With Antigen 1 Antibody SCR | From Day 1 (baseline) to Day 29 | SCR is defined as the percentage of dosed participants who have either an anti-vaccine antibody pre-dose titer \< 1:10 and a post-dose anti-vaccine antibody titer \>= 1:40 or a pre-dose anti-vaccine antibody titer \>= 1:10 and at least a 4-fold increase in post-dose anti-vaccine antibody titer. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR) | At Day 1 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 YA: Percentage of Participants With Antigen 1 Antibody SPR | At Day 1 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 OA: Percentage of Participants With Antigen 1 Antibody SPR | At Day 1 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 2 OA: Percentage of Participants With Antigen 1 Antibody SPR | At Day 1 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
| Part 1 YA: Percentage of Participants With Antigen 1 Antibody SPR | At Day 29 | SPR is defined as the percentage of dosed participants with a anti-vaccine antibody titer \>= 1:40. Assay 1= with egg propagated Influenza virus and Assay 2= with cell propagated Influenza virus. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1 YA: GMT of Antigen 2 Antibody Titer | At Day 29 | — |
| Part 2 YA: GMT of Antigen 2 Antibody Titer | At Day 29 | — |
| Part 1 OA: GMT of Antigen 2 Antibody Titer | At Day 29 | — |
| Part 2 OA: GMT of Antigen 2 Antibody Titer | At Day 29 | — |
| Part 1 YA: GMI of Antigen 2 Antibody Titer | From Day 1 (baseline) to Day 29 | — |
| Part 2 YA: GMI of Antigen 2 Antibody Titer | From Day 1 (baseline) to Day 29 | — |
| Part 1 OA: GMI of Antigen 2 Antibody Titer | From Day 1 (baseline) to Day 29 | — |
| Part 2 OA: GMI of Antigen 2 Antibody Titer | From Day 1 (baseline) to Day 29 | — |
| Part 1 YA: Percentage of Participants With Antigen 2 Antibody SCR | From Day 1 (baseline) to Day 29 | — |
| Part 2 YA: Percentage of Participants With Antigen 2 Antibody SCR | From Day 1 (baseline) to Day 29 | — |
| Part 1 OA: Percentage of Participants With Antigen 2 Antibody SCR | From Day 1 (baseline) to Day 29 | — |
| Part 2 OA: Percentage of Participants With Antigen 2 Antibody SCR | From Day 1 (baseline) to Day 29 | — |
| Part 1 YA: Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) | Day 1 to Day 7 | Assessed solicited administration site events included pain, redness (erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting Any Solicited Administration Site AEs | Day 1 to Day 7 | Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting Any Solicited Administration Site AEs | Day 1 to Day 7 | Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting Any Solicited Administration Site AEs | Day 1 to Day 7 | Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade. |
| Part 1 YA: Number of Participants Reporting Any Solicited Systemic AEs | Day 1 to Day 7 | Assessed solicited systemic events included fever (pyrexia) which is defined as axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F, chills, headache, fatigue (tiredness), myalgia (muscle joint), and arthralgia (joint pain). Any = occurrence of the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting Any Solicited Systemic AEs | Day 1 to Day 7 | Assessed solicited systemic events included fever (pyrexia) which is defined as axillary temperature \>= 38.0°C/100.4°F, chills, headache, fatigue (tiredness), myalgia (muscle joint), and arthralgia (joint pain). Any = occurrence of the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting Any Solicited Systemic AEs | Day 1 to Day 7 | Assessed solicited systemic events included fever (pyrexia) which is defined as axillary temperature \>= 38.0°C/100.4°F, chills, headache, fatigue (tiredness), myalgia (muscle joint), and arthralgia (joint pain). Any = occurrence of the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting Any Solicited Systemic AEs | Day 1 to Day 7 | Assessed solicited systemic events included fever (pyrexia) which is defined as axillary temperature \>= 38.0°C/100.4°F, chills, headache, fatigue (tiredness), myalgia (muscle joint), and arthralgia (joint pain). Any = occurrence of the event regardless of intensity grade. |
| Part 1 YA: Number of Participants Reporting Any Unsolicited AEs | Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting Any Unsolicited AEs | Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting Any Unsolicited AEs | Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting Any Unsolicited AEs | Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence the event regardless of intensity grade. |
| Part 1 YA: Number of Participants Reporting Serious Adverse Events (SAEs) | Day 1 to Day 183 | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting SAEs | Day 1 to Day 183 | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting SAEs | Day 1 to Day 183 | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting SAEs | Day 1 to Day 183 | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product. Any = occurrence the event regardless of intensity grade. |
| Part 1 YA: Number of Participants Reporting AEs of Special Interest (AESIs) | Day 1 to Day 183 | The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting AESIs | Day 1 to Day 183 | The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting AESIs | Day 1 to Day 183 | The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting AESIs | Day 1 to Day 183 | The following events were considered as AESI in this study: severe hypersensitivity reactions within 24 hours after study intervention administration, myocarditis/pericarditis and potential immune-mediated diseases (pIMDs). Any = occurrence the event regardless of intensity grade. |
| Part 1 YA: Number of Participants Reporting Medically Attended Adverse Events (MAAEs) | Day 1 to Day 183 | MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade. |
| Part 2 YA: Number of Participants Reporting MAAEs | Day 1 to Day 183 | MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade. |
| Part 1 OA: Number of Participants Reporting MAAEs | Day 1 to Day 183 | MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade. |
| Part 2 OA: Number of Participants Reporting MAAEs | Day 1 to Day 183 | MAE is defined as an AE that results in an unscheduled visit to a medical professional (e.g., physician's office visits, emergency room visits or hospitalization). Any = occurrence the event regardless of intensity grade. |
Countries
United States
Participant flow
Pre-assignment details
A total of 845 participants were included in enrolled set out of which only 833 were included in exposed set and started the study.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized 18-64 years | 80 Participants |
| Age, Customized 65-84 years | 0 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants |
| Race/Ethnicity, Customized Asian | 8 Participants |
| Race/Ethnicity, Customized Black or African American | 11 Participants |
| Race/Ethnicity, Customized MULTIPLE | 0 Participants |
| Race/Ethnicity, Customized NOT REPORTED | 0 Participants |
| Race/Ethnicity, Customized UNKNOWN | 0 Participants |
| Race/Ethnicity, Customized WHITE | 679 Participants |
| Sex: Female, Male Female | 26 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 50 | 0 / 50 | 0 / 48 | 0 / 50 | 0 / 52 | 0 / 81 | 0 / 80 | 0 / 51 | 0 / 52 | 0 / 53 | 0 / 51 | 0 / 53 | 0 / 82 | 0 / 80 |
| other Total, other adverse events | 31 / 50 | 33 / 50 | 33 / 48 | 34 / 50 | 29 / 52 | 54 / 81 | 39 / 80 | 37 / 51 | 39 / 52 | 39 / 53 | 40 / 51 | 36 / 53 | 48 / 82 | 33 / 80 |
| serious Total, serious adverse events | 0 / 50 | 1 / 50 | 1 / 48 | 2 / 50 | 2 / 52 | 0 / 81 | 0 / 80 | 3 / 51 | 2 / 52 | 3 / 53 | 1 / 51 | 0 / 53 | 0 / 82 | 0 / 80 |
Outcome results
None listed